Blueprint Medicines Corp (BPMC) - Total Assets
Based on the latest financial reports, Blueprint Medicines Corp (BPMC) holds total assets worth $1.20 Billion USD as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore BPMC cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Blueprint Medicines Corp - Total Assets Trend (2013–2024)
This chart illustrates how Blueprint Medicines Corp's total assets have evolved over time, based on quarterly financial data. See Blueprint Medicines Corp net assets for net asset value and shareholders' equity analysis.
Blueprint Medicines Corp - Asset Composition Analysis
Current Asset Composition (December 2024)
Blueprint Medicines Corp's total assets of $1.20 Billion consist of 63.0% current assets and 37.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 8.7% |
| Accounts Receivable | $77.61 Million | 6.6% |
| Inventory | $13.61 Million | 1.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Blueprint Medicines Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Blueprint Medicines Corp market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Blueprint Medicines Corp's current assets represent 63.0% of total assets in 2024, an increase from 59.2% in 2013.
- Cash Position: Cash and equivalents constituted 8.7% of total assets in 2024, down from 48.1% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 6.6% of total assets.
Blueprint Medicines Corp Competitors by Total Assets
Key competitors of Blueprint Medicines Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Akero Therapeutics Inc
NASDAQ:AKRO
|
USA | $1.01 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Zealand Pharma A/S
CO:ZEAL
|
Denmark | Dkr16.46 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Immunitybio Inc
NASDAQ:IBRX
|
USA | $518.99 Million |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
Blueprint Medicines Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.80 | 3.76 | 5.41 |
| Quick Ratio | 2.75 | 3.61 | 5.37 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $451.49 Million | $570.00 Million | $463.23 Million |
Blueprint Medicines Corp - Advanced Valuation Insights
This section examines the relationship between Blueprint Medicines Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 24.44 |
| Latest Market Cap to Assets Ratio | 7.09 |
| Asset Growth Rate (YoY) | 12.4% |
| Total Assets | $1.18 Billion |
| Market Capitalization | $8.36 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Blueprint Medicines Corp's assets at a significant premium (7.09x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Blueprint Medicines Corp's assets grew by 12.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Blueprint Medicines Corp (2013–2024)
The table below shows the annual total assets of Blueprint Medicines Corp from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.18 Billion | +12.44% |
| 2023-12-31 | $1.05 Billion | -22.27% |
| 2022-12-31 | $1.35 Billion | +7.80% |
| 2021-12-31 | $1.25 Billion | -27.13% |
| 2020-12-31 | $1.72 Billion | +142.82% |
| 2019-12-31 | $707.69 Million | +31.02% |
| 2018-12-31 | $540.12 Million | -24.54% |
| 2017-12-31 | $715.74 Million | +153.09% |
| 2016-12-31 | $282.80 Million | +58.08% |
| 2015-12-31 | $178.90 Million | +258.33% |
| 2014-12-31 | $49.92 Million | +1107.38% |
| 2013-12-31 | $4.13 Million | -- |
About Blueprint Medicines Corp
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast … Read more